Oncology Drugs Market Report 2018-2026 Focuses On Top Companies Hoffmann-La Roche AG, Novartis International AG, Celgene Corporation, Johnson & Johnson, Bristol-Myers Squibb, Pfizer

Cancer is one of the deadliest disease with less chance of survival as the disease progresses. International Agency for Research on Cancer published GLOBOCAN 2018 report, which estimates cancer incidence and mortality rate. This report focus on geographic variability of cancer incidence rate and mortality rate across 20 world regions. This report projected 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. Therefore, high prevalence of cancer is expected to be major factor for growth of the global oncology drugs market.

The global oncology drugs market is one of the fastest growing market in overall pharmaceutical and biotech market. Major reasons for growth of this market are,

1.Increasing prevalence of various types of cancer worldwide

2.Increasing early stage detection rate of cancer

3.Robust pipeline of drugs and biologics-based products and increased number of oncology drugs receiving regulatory approvals

4.Increasing investment by the pharmaceutical companies in research and development of oncology drugs

5.Increasing number of blockbuster drugs going off patent resulting in entry of new generics and biosimilars in the market

6.Growing commercial tie ups amongst key players for either drug development, marketing, or distribution of the product

Get FREE Request Sample Copy Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/2332

According to a report by Pharmaceutical Research and Manufacturers Association in 2015, over 800 drugs are in development stage targeting various types of cancer. Moreover, same source suggested that around 73% of personalized medicine under development are targeted towards cancer. Melanoma, colorectal cancer, blood cancer, breast cancer, lung cancer, and prostate cancer are the most targeted cancer for drug development. According to International Federation of the Pharmaceutical Manufacturers Association’s report published in 2017, in 2014, the number of drugs in development for cancer was 1,919.

The global oncology drugs market is expected to witness a CAGR of 12.5% during the forecast period (2018 – 2026), owing to increasing approvals for immunotherapy-based drugs

Among drug type, targeted drugs segment is expected to hold position in the market over the forecast period. This is owing to increasing adoption of targeted therapy due to lower side effects as compared to chemotherapy drugs
Among caner type, lung cancer segment is expected to hold dominant position in the market over the forecast period. This is attributed to high number of approved drugs for lung cancer and increasing incidence of the disease.
Among distribution channel, hospital pharmacies segment is expected to hold dominant position over the forecast period as reimbursement and pricing of drugs are more favorable in hospital pharmacies, owing to 340B pricing program
Key players operating in the global oncology drugs market include, Hoffmann-La Roche AG, Novartis International AG, Celgene Corporation, Johnson & Johnson, Bristol-Myers Squibb, Pfizer Inc., Merck & Co., Eli Lilly and Company, AbbVie, Inc., AstraZeneca plc, Bayer AG, and Amgen Inc.

Click To Reading More On Oncology Drugs Market
https://www.coherentmarketinsights.com/market-insight/oncology-drugs-market-2332

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702

This release was published on openPR.